Mechanism of Action
Tesamorelin stimulates pulsatile GH secretion through GHRH receptor agonism, with activity profile between Sermorelin (29aa) and CJC-1295 (with DAC).
GHRH Receptor Agonism and GH Pulsatility
Tesamorelin binds GHRH receptors with the full binding domain of GHRH(1-44) while the hexenoic acid modification prevents DPP-IV cleavage of the N-terminal Tyr-Ala bond. This doubles effective half-life versus native GHRH while preserving pulsatile GH secretion that mimics physiological patterns.[1]Visceral Adipose Tissue Reduction
GH/IGF-1 elevation from Tesamorelin preferentially mobilizes visceral adipose tissue (VAT) versus subcutaneous fat. VAT reduction is the primary clinical endpoint in HIV lipodystrophy trials. The mechanism involves GH receptor-mediated induction of hormone-sensitive lipase in visceral adipocytes, with IGF-1-mediated effects on adipokine regulation.[2]Preservation of Pituitary Feedback
As a GHRH analog (not direct GH), Tesamorelin preserves somatostatin-mediated negative feedback and GH receptor regulation. This is clinically relevant for long-term use, GH pulsatility is maintained without progressive downregulation seen with continuous GH agonists.[1]Research Overview
HIV Lipodystrophy (FDA Approved)
Phase III ClinicalPhase III TERAPIA trials demonstrated 15-18% reduction in visceral adipose tissue over 26 weeks in HIV-positive patients with lipodystrophy. Trunk fat measured by CT scan was significantly reduced. FDA approved Egrifta in 2010 for this indication; a higher-dose formulation (Egrifta SV) approved in 2019 for easier reconstitution.[1]
Metabolic and Body Composition
Phase II ClinicalBeyond HIV, Phase II data shows IGF-1 elevation, lean mass preservation, and VAT reduction in non-HIV adults with abdominal adiposity. Cardiovascular risk markers (triglycerides, carotid intima-media thickness) also improved in Phase II trials.[2]
Cognitive Effects
EmergingA Phase II trial in older adults with mild cognitive impairment showed improved executive function, memory scores, and reduced amyloid burden on PET imaging with 20-week Tesamorelin treatment. GH/IGF-1 restoration may support neuronal maintenance in aging brain.[3]
Calculate your Tesamorelin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Clinical Trial Data
| Phase | Trial | N | Duration | Key Outcome |
|---|---|---|---|---|
| Phase 3 | EFFECTS trial (HIV lipodystrophy) PMID:21281421 | 816 | 52 weeks | Mean VAT reduction 17.8% vs placebo; trunk fat decreased 3.1 kg; IGF-1 normalized; FDA approval basis |
| Phase 3 | Falutz et al. pivotal trial PMID:20547902 | 412 | 26 weeks | VAT area reduced 18% by abdominal MRI; trunk fat reduced 13%; primary endpoint met for FDA registration |
| Phase 2 | NASH / metabolic (off-label obese) PMID:26990626 | 61 | 26 weeks | Significant liver fat reduction by MRI; improved insulin resistance; favorable safety profile in non-HIV population |
| Phase 2 | Cognitive impairment (MCI adults) PMID:22486578 | 152 | 20 weeks | Improved executive function and verbal memory; reduced amyloid on PET; supports CNS GH/IGF-1 axis relevance |
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| FDA protocol (HIV lipodystrophy) | 2 mg | Once daily | Subcutaneous |
| Body composition / anti-aging | 1 mg | Once daily (bedtime) | Subcutaneous |
| Stacked with Ipamorelin | 1 mg Tesamorelin + 200 µg Ipamorelin | Bedtime | Subcutaneous |
Bedtime dosing amplifies the natural nocturnal GH pulse. The combination with Ipamorelin provides both GHRH and GHRP components for maximal GH pulsatility. Fasted state preferred for GH optimization.
Research protocols only. FDA approved dose: 2 mg SC once daily for HIV lipodystrophy.
Peptide Interactions
Safety Profile
Tesamorelin has an FDA-approved safety profile from large Phase III trials.
WADA: Prohibited as a peptide hormone and growth factor.
FDA approved: Egrifta (1 mg) and Egrifta SV (2 mg) approved for HIV lipodystrophy. Largest clinical safety dataset of any GHRH analog.
Common adverse effects: Peripheral edema, arthralgia, myalgia, and injection site reactions are most common in Phase III trials. Usually mild and manageable.
IGF-1 monitoring: IGF-1 elevation should be monitored; treatment should be suspended if IGF-1 exceeds age-adjusted upper normal limit.
Glucose: GH-related insulin resistance can emerge. Monitor glucose, particularly in pre-diabetic patients.
References
- [1]Falutz J, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." N Engl J Med. 2007;357(23):2359-2370.
- [2]Falutz J, et al. "Effects of long-term therapy with tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat: two-year data from a phase III trial." Clin Infect Dis. 2010;51(5):656-665.
- [3]Baker LD, et al. "Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults." Arch Neurol. 2012;69(11):1420-1429.